03/01/2012  -ATIN-  Since drug developer Alkermes (Nasdaq ALKS) took over marketing of its VIVITROL anti-craving medication from former partner Cephalon, which burnt through as astounding $250M and was only able to push sales of the addition pharmaceutical to $20M over a period of several years, VIVITROL sales have been steadily increasing. That trend continued in the fourth quarter with net sales of the drug reaching $10.8M compared to $7.7 million for the same period in 2011, representing a 38% increase year-over-year. Compared to $9.9 million in the third quarter of  2011, VIVITROL fourth quarter sales represented a 7% sequential quarterly increase. Alkermes has now managed to ramp sales of VIVITROL for ten consecutive quarters.

Newswire Staff

This e-mail address is being protected from spambots. You need JavaScript enabled to view it

561-702-4235

TrackBack URI for this entry

Comments (0)

Subscribe to this comment's feed

Name

Email

Website

Title

Comment

smaller | bigger

Add Comment